Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
Top Cited Papers
- 11 September 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 384 (9961), 2228-2234
- https://doi.org/10.1016/s0140-6736(14)61335-0
Abstract
No abstract availableFunding Information
- Ontario Ministry of Research, Innovation and Science
- Canadian Diabetes Association
- Heart and Stroke Foundation of Canada
This publication has 28 references indexed in Scilit:
- Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesityCardiovascular Diabetology, 2012
- Combination therapy with GLP‐1 receptor agonists and basal insulin: a systematic review of the literatureDiabetes, Obesity and Metabolism, 2012
- Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal‐L‐Asia)Diabetes, Obesity and Metabolism, 2012
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Type 2 diabetes across generations: from pathophysiology to prevention and managementThe Lancet, 2011
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormalityDiabetologia, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002